| Literature DB >> 32265719 |
Yijun Zheng1, Weiyu Ren2, Lina Zhang3, Yuemei Zhang4, Dongling Liu1,2, Yongqi Liu1.
Abstract
Astragalus membranaceus (A. membranaceus) is a type of traditional Chinese medicine with a long history of clinical application. It is used in the improvement and treatment of various diseases as medicine and food to invigorate the spleen and replenish qi. The main components of A. membranaceus are Astragalus polysaccharide (APS), flavonoids compounds, saponins compounds, alkaloids, etc. APS is the most important natural active component in A. membranaceus, and possesses multiple pharmacological properties. At present, APS possess the huge potential to develop a drug improving or treating different diseases. In this review, we reveal the potential approaches of pre-treating and preparation on APS as much as possible and the study on content of APS and its chemical composition including different monosaccharides. More importantly, this paper summarize pharmacological actions on immune regulation, such as enhancing the immune organ index, promoting the proliferation of immune cells, stimulating the release of cytokines, and affecting the secretion of immunoglobulin and conduction of immune signals; anti-aging; anti-tumor by enhancing immunity, inducing apoptosis of tumor cells and inhibiting the proliferation and transfer of tumor cells; antiviral effects; regulation of blood glucose such as type I diabetes mellitus, type II diabetes mellitus and diabetic complications; lipid-lowering; anti-fibrosis; antimicrobial activities and anti-radiation. It provided theoretical basis for the further research such as its structure and mechanism of action, and clinical application of APS.Entities:
Keywords: Astragalus polysaccharide; anti-aging; anti-tumor; chemical composition; immune regulation; pharmacological action; preparation; regulation of blood glucose
Year: 2020 PMID: 32265719 PMCID: PMC7105737 DOI: 10.3389/fphar.2020.00349
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Nine pharmacological effects of APS. This figure shows the most highlighted nine effects in studies on APS.
Influences of APS on cytokines.
| Cytokine | Influence | Model | Reference |
|---|---|---|---|
| IL1β | Upregulation | ( | |
| Downregulation | ( | ||
| ( | |||
| IL2 | Upregulation | ( | |
| ( | |||
| IL3 | Upregulation | ( | |
| IL4 | Upregulation | ( | |
| IL6 | Upregulation | ( | |
| ( | |||
| Downregulation | ( | ||
| IL8 | Downregulation | ( | |
| IL10 | Upregulation | ( | |
| Downregulation | ( | ||
| IL11 | Upregulation | ( | |
| IL12 | Upregulation | ( | |
| Downregulation | ( | ||
| IFNγ | Upregulation | ( | |
| Downregulation | ( | ||
| TGF-β | Upregulation | ( | |
| TNF-α | Upregulation | ( | |
| ( | |||
| Downregulation | ( | ||
| ( |
Figure 2APS exerts different effects on the signaling pathways in different environments and under certain physiological conditions.
Antitumor effect mechanism of APS.
| Pharmacological action | Function | Living model | Reference |
|---|---|---|---|
| Inhibition of tumor cell proliferation | Downregulation of cyclin B and cyclin E expression and upregulation of P21 expression | K562 cells | ( |
| Blockage of cells in the G0-G1 phase | MKN45 cells HgpG2 cells | ( | |
| Decrease in proliferating nuclear antigen expression | COLO205 cells | ( | |
| Cell blockage in the G1 phase; cells in the S phase were obviously reduced | BEL-7404 cells | ( | |
| Reduction of transcriptional activity of P65mRNA in cells, reduction of LC3B and beclin 1 expression | A549 cells | ( | |
| Increase of BAX protein expression, decrease of BCL2 protein expression | H22 cells | ( | |
| H22 tumor-bearing mice | ( | ||
| Regulation of CDC6 and CCNB1 | MCF-7 cells | ( | |
| Promote tumor cells apoptosis | Cell blockage in the G1 phase; cells in the S phase were obviously reduced | MCF-7 cells | ( |
| 4T1 cells | ( | ||
| Promotion of cell differentiation into the G0-G1 and G0-M phases, decrease in the S phase | HgpG2 cells | ( | |
| Inhibition of the ERK1/2 signaling pathway | HgpG2 cells | ( | |
| Inhibition of the transcriptional activity of NF-κB | A549 cells | ( | |
| Decrease in BCL2 expression, increase in caspase 3 activity | HgpG2 cells | ( | |
| Increase in the levels of BAX and caspase 8, and decrease in the levels of BCL2 | H460 cells | ( | |
| Downregulation of BAX and BCL2 expression | SGC7901 cells | ( | |
| Reduction of telomerase activity | HL-60 cells | ( | |
| Increase in intracellular calcium concentration | S-180 cells | ( | |
| Inhibit tumor cell metastasis | Decrease in MMP2 | C-33A cells | ( |
| Up-regulation of E-cadherin expression, inhibition of MMP2 | C-4I cells | ( | |
| Inhibition of NOTCH1 expression | H22 cells | ( | |
| Inhibition of the NF-κB and MAPK signaling pathways | Lewis cells | ( |
Figure 3Regulation on blood glucose by APS. The effect of APS on DM mainly involves reduction of IR, promotion of the proliferation of islet cells, and inhibition of the apoptosis of islet β cells. The intrinsic mechanism of its pharmacological action mainly involves influencing the expression of related genes and proteins.